Literature DB >> 6204766

An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

J B Konopka, S M Watanabe, O N Witte.   

Abstract

The v-abl protein is known to be a tyrosine-specific protein kinase. However, its normal cellular homolog, c-abl P150, is not detectably phosphorylated on tyrosine in vivo or in vitro. The lack of associated tyrosine kinase activity for the c-abl protein seems paradoxical since it is the c-abl-derived sequences of the v-abl protein that encode the kinase activity. We have detected an altered human c-abl protein (P210) with associated tyrosine kinase activity in the K562 leukemia cell line. K562 cells are known to have a 9:22 chromosomal translocation involving the c-abl locus and have amplified the c-able gene 4 to 8 fold. The altered P210 human c-abl is serologically and structurally related to the normal c-abl protein. A structural alteration of the human c-abl protein. K562 cells may have unmasked its associated tyrosine kinase activity. This altered c-abl protein may have important implications for a mechanism of activation of this oncogene.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6204766     DOI: 10.1016/0092-8674(84)90438-0

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  181 in total

Review 1.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

Authors:  B J Druker; N B Lydon
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.

Authors:  T Kuwabara; M Warashina; T Tanabe; K Tani; S Asano; K Taira
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

3.  Molecular biology of Philadelphia chromosome in chronic granulocytic leukaemia and acute lymphoblastic leukaemia.

Authors:  S Eridani; L M Wiedemann; L C Chan; R G Dalton; K K Karhi
Journal:  Cytotechnology       Date:  1987-10       Impact factor: 2.058

4.  The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; Z Arlin; S Advani; S L Allen; J Goldman; D Snyder; A Foti; M Cline
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 5.  Treatment for chronic myelogenous leukemia: the long road to imatinib.

Authors:  Tony Hunter
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 6.  Applying the discovery of the Philadelphia chromosome.

Authors:  Daniel W Sherbenou; Brian J Druker
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

7.  Molecular cloning of the breakpoints of a complex Philadelphia chromosome translocation: identification of a repeated region on chromosome 17.

Authors:  T W McKeithan; L Warshawsky; R Espinosa; M M LeBeau
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

8.  Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures.

Authors:  J C Young; O N Witte
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

9.  Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.

Authors:  M L Gishizky; D Cortez; A M Pendergast
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

10.  Transcriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinases.

Authors:  L Cohen; R Mohr; Y Y Chen; M Huang; R Kato; D Dorin; F Tamanoi; A Goga; D Afar; N Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.